| Bioactivity | Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1]. |
| Invitro | Geptanolimab (CBT-501) 与人 (KD=505 pM) 和猕猴 (KD=7.2 nM) 的 PD-1 具有高度特异性结合[ 1]。Geptanolimab 增强混合淋巴细胞反应 (MLR) 中的人 T 细胞活化，增加 IL-2 和 INF-γ 的释放[1]。 |
| In Vivo | Geptanolimab (CBT-501; ip; 每两周一次, 持续6周; MC38同系肿瘤模型小鼠) 具有抗肿瘤活性，抑瘤率达到 83%[1]。 |
| Name | Geptanolimab |
| CAS | 2348469-43-0 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7_suppl):108-108. |